220 related articles for article (PubMed ID: 19554084)
1. What is the optimal therapy for patients with H5N1 influenza?
White NJ; Webster RG; Govorkova EA; Uyeki TM
PLoS Med; 2009 Jun; 6(6):e1000091. PubMed ID: 19554084
[TBL] [Abstract][Full Text] [Related]
2. Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience.
Smith JR; Rayner CR; Donner B; Wollenhaupt M; Klumpp K; Dutkowski R
Adv Ther; 2011 Nov; 28(11):927-59. PubMed ID: 22057727
[TBL] [Abstract][Full Text] [Related]
3. Oseltamivir resistance among influenza viruses: surveillance in northern Viet Nam, 2009-2012.
Hoang Vu MP; Nguyen CT; Nguyen le KH; Nguyen TK; Le QM
Western Pac Surveill Response J; 2013; 4(2):25-9. PubMed ID: 24015368
[TBL] [Abstract][Full Text] [Related]
4. [Threat from newly emerging influenza].
Kashiwagi S
Nihon Naika Gakkai Zasshi; 2007 Apr; 96(4):811-6. PubMed ID: 17506323
[No Abstract] [Full Text] [Related]
5. Using oseltamivir (Tamiflu) as a first line treatment for seasonal or pandemic flu.
Greener M
Nurs Times; 2009 Sep 1-7; 105(34):22. PubMed ID: 19788111
[No Abstract] [Full Text] [Related]
6. [Etiotropic therapy of influenza: lessons from the last pandemic].
Kolobukhina LV; Shchelkanov MIu; Merkulova LN; Bazarova MV; Burtseva EI; Samokhvalov EI; Al'khovskiĭ SV; Prilipov AG; Fediakina IT; Proshina ES; Aristova VA; Morozova TN; Sutochnikova OA; Ponomarenko RA; Malyshev NA; Maslov AM; Chuchalin AG
Vestn Ross Akad Med Nauk; 2011; (5):35-40. PubMed ID: 21786595
[TBL] [Abstract][Full Text] [Related]
7. The use of antiviral agents for the management of severe influenza.
Smith JR; Ariano RE; Toovey S
Crit Care Med; 2010 Apr; 38(4 Suppl):e43-51. PubMed ID: 19935416
[TBL] [Abstract][Full Text] [Related]
8. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
Ikematsu H; Kawai N
Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
[TBL] [Abstract][Full Text] [Related]
9. [Oseltamivir resistant avian influenza unsettling. Private hoarding of influenza agents a potential threat against public health].
Uhnoo I; Linde A
Lakartidningen; 2006 Feb 1-7; 103(5):298-300. PubMed ID: 16512569
[No Abstract] [Full Text] [Related]
10. [Susceptibility of pandemic influenza virus A 2009 H1N1 and highly pathogenic avian influenza virus A H5N1 to antiinfluenza agents in cell culture].
Fediakina IT; Shchelkanov MIu; Deriabin PG; Leneva IA; Gudova NV; Kondrat'eva TV; L'vov DK
Antibiot Khimioter; 2011; 56(3-4):3-9. PubMed ID: 21913403
[TBL] [Abstract][Full Text] [Related]
11. Possible neuropsychiatric reaction to high-dose oseltamivir during acute 2009 H1N1 influenza A infection.
Nakamura K; Schwartz BS; Lindegårdh N; Keh C; Guglielmo BJ
Clin Infect Dis; 2010 Apr; 50(7):e47-9. PubMed ID: 20192728
[TBL] [Abstract][Full Text] [Related]
12. The pharmacological management of severe influenza infection - 'existing and emerging therapies'.
Mc Mahon A; Martin-Loeches I
Expert Rev Clin Pharmacol; 2017 Jan; 10(1):81-95. PubMed ID: 27797595
[TBL] [Abstract][Full Text] [Related]
13. Oseltamivir in the management of influenza.
Oxford J
Expert Opin Pharmacother; 2005 Nov; 6(14):2493-500. PubMed ID: 16259580
[TBL] [Abstract][Full Text] [Related]
14. Foreword: Oseltamivir for seasonal, avian and pandemic influenza: 10 years of clinical experience.
Nguyen-Van-Tam JS
J Antimicrob Chemother; 2010 Apr; 65 Suppl 2(Suppl 2):ii3-ii4. PubMed ID: 20215133
[No Abstract] [Full Text] [Related]
15. Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.
Widmer N; Meylan P; Ivanyuk A; Aouri M; Decosterd LA; Buclin T
Clin Pharmacokinet; 2010 Nov; 49(11):741-65. PubMed ID: 20923248
[TBL] [Abstract][Full Text] [Related]
16. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
Ilyushina NA; Hoffmann E; Salomon R; Webster RG; Govorkova EA
Antivir Ther; 2007; 12(3):363-70. PubMed ID: 17591026
[TBL] [Abstract][Full Text] [Related]
17. Determinants of antiviral effectiveness in influenza virus A subtype H5N1.
Chan PK; Lee N; Zaman M; Adisasmito W; Coker R; Hanshaoworakul W; Gasimov V; Oner AF; Dogan N; Tsang O; Phommasack B; Touch S; Bamgboye E; Swenson A; Toovey S; Dreyer NA
J Infect Dis; 2012 Nov; 206(9):1359-66. PubMed ID: 22927451
[TBL] [Abstract][Full Text] [Related]
18. The combination of oseltamivir with azithromycin does not show additional benefits over oseltamivir monotherapy in mice infected with influenza A(H1N1)pdm2009 virus.
Fage C; Pizzorno A; Rhéaume C; Abed Y; Boivin G
J Med Virol; 2017 Dec; 89(12):2239-2243. PubMed ID: 28792077
[TBL] [Abstract][Full Text] [Related]
19. Simvastatin and oseltamivir combination therapy does not improve the effectiveness of oseltamivir alone following highly pathogenic avian H5N1 influenza virus infection in mice.
Belser JA; Szretter KJ; Katz JM; Tumpey TM
Virology; 2013 Apr; 439(1):42-6. PubMed ID: 23453580
[TBL] [Abstract][Full Text] [Related]
20. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.
Wang SQ; Du QS; Huang RB; Zhang DW; Chou KC
Biochem Biophys Res Commun; 2009 Aug; 386(3):432-6. PubMed ID: 19523442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
